William Blair analyst Myles Minter has reiterated their bullish stance on VRTX stock, giving a Buy rating on March 28.
Myles Minter has given his Buy rating due to a combination of factors surrounding Vertex Pharmaceuticals’ advancements in their type 1 diabetes program. The company is making significant strides with zimislecel (VX-880), an islet cell therapy that is currently in the pivotal Phase III portion of its clinical trials. This therapy aims to address severe hypoglycemic events in T1D patients, and early data has shown promising results, with all evaluable patients achieving glycemic control and reduced reliance on exogenous insulin.
Minter’s confidence in Vertex is further bolstered by the company’s strategic focus on innovative cell-based therapies that could potentially transform diabetes treatment. Despite the discontinuation of VX-264 due to unmet efficacy endpoints, the ongoing progress with zimislecel and its potential regulatory filing in 2026 highlight Vertex’s commitment to advancing its pipeline. This forward-looking approach, coupled with the company’s ability to navigate setbacks and focus on promising assets, underpins Minter’s Buy rating for Vertex Pharmaceuticals.
In another report released on March 28, Citi also maintained a Buy rating on the stock with a $575.00 price target.